In terms of market performance, AbCellera Biologics Inc had a somewhat inconsistent run in. The highest value for the stock in the past year was $6.05 on 01/08/24, while the lowest value was $2.34 on 09/10/24.
52-week price history of ABCL Stock
Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. AbCellera Biologics Inc’s current trading price is -49.66% away from its 52-week high, while its distance from the 52-week low is 30.54%. The stock’s price range for this period has remained between $2.34 and $6.05. The Healthcare sector company’s shares managed to surpass a trading volume of around 1.19 million for the day, which was noticeably lower compared to the shares’ average daily volume of 2.18 million over the last three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Financial Performance and Market Capitalization
AbCellera Biologics Inc (ABCL) has experienced a quarterly rise of 20.47% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 900.28M and boasts a workforce of 586 employees.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.75, with a change in price of +0.21. Similarly, AbCellera Biologics Inc recorded 1,928,210 in trading volume during the last 100 days, posting a change of +7.45%.
ABCL Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ABCL stands at 0.07. Similarly, the long-term debt-to-equity ratio is also 0.06.
ABCL Stock Stochastic Average
As of today, the raw stochastic average of AbCellera Biologics Inc over the past 50 days is 80.52%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 77.94%. Additionally, the Stochastic %K and %D values for the company were 64.22% and 53.59%, respectively, over the past 20 days.
ABCL Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The index has shown a price loss of -46.62% this year. Over the last six months, there has been a stronger performance of -24.55%. The price of ABCL fallen by 7.70% during the last 30 days period. For the last 5-days stocks have improved 14.16%.
